We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03536234
Recruitment Status : Unknown
Verified January 2021 by Immune System Regulation AB.
Recruitment status was:  Recruiting
First Posted : May 24, 2018
Last Update Posted : January 13, 2021
Sponsor:
Information provided by (Responsible Party):
Immune System Regulation AB

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
An open, randomised, parallel arm phase IIa study. 52 HIV-1 infected patients will be randomised (in a 1:1 ratio) to either an active group or a control group. The active group will receive the GnRH analogue triptorelin depot monthly at baseline, week 4 and week 8. Patients in the active group and in the control group will continue their triple combination antiretroviral therapy (ART) during the study without changes; unless there is rationale for change on medical ground. In order to prevent the negative effects of a low testosterone level, patients in the active group will be offered to receive a single intramuscular depot injection of testosterone approximately 7 days after triptorelin treatment. This depot administration will keep the serum testosterone on a normal level until the next triptorelin dose. This will be repeated when triptorelin is administered at week 4 and week 8. Total study period is 24 weeks.

Condition or disease Intervention/treatment Phase
HIV-1-infection Drug: Triptorelin acetate depot Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients
Actual Study Start Date : September 19, 2018
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Triptorelin (GnRH analogue) Drug: Triptorelin acetate depot
3.75 mg triptorelin depot (monthly injections). 3 doses in total
No Intervention: Control group


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Mean change from baseline to week 12 in total HIV-1 DNA levels in CD4+ cells in the active group compared to the mean change in the control group. [ Time Frame: Baseline to 12 weeks time point ]

Secondary Outcome Measures :
  1. Mean change of the HLA class 1 expression from baseline to week 12 in the active group compared to the mean change in the control group [ Time Frame: Baseline to 12 weeks time point ]
  2. Mean change in the CD4+ T-cell counts from baseline to week 12 in the active group compared to the mean change in the control group. [ Time Frame: Baseline to 12 weeks time point ]
  3. Mean change in the CD8+ T-cell counts from baseline to week 12 in the active group compared to the mean change in the control group. [ Time Frame: Baseline to 12 weeks time point ]
  4. Number of adverse events in active group compared to control group [ Time Frame: Baseline to 12 weeks time point ]
    Adverse events will be presented by Medical Dictionary for Regulatory Activities MedDRA) preferred term (PT) and system organ class (SOC).

  5. Number and percentage of patients reporting any adverse events in active group compared to control group [ Time Frame: Baseline to 12 weeks time point ]
    Number and percentage of patients reporting any adverse event will be be presented by MedDRA PT and SOC.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male gender
  2. 18 to 65 years of age, inclusive, at the time of informed consent
  3. Ability and willingness to give a written or orally witnessed informed consent
  4. HIV-1 infection as documented by HIV antibody test
  5. CD4+ cell count >300 cells/μL at screening
  6. Total HIV-1 DNA level between 100 to 5000 copies/million PBMC as measured by real-time PCR within 4 months prior to screening
  7. Plasma HIV-1 RNA level <50 copies/mL for the last year (one blip allowed; blip defined as HIV RNA between 50-150 copies/mL) including a plasma HIV-1 RNA level <50 copies/mL at screening
  8. On triple combination ART (two nucleoside reverse transcriptase inhibitors (NRTI) + one integrase inhibitor or protease inhibitor or one non-NRTI (NNRTI)) for minimum 36 months (assessed at screening)
  9. Currently on continuous triple combination ART as specified above (i.e. no changes in medication) the past 4 months prior to screening

Exclusion Criteria:

  1. Treatment failure while on triple ART
  2. Nadir CD4+ count < 200 cells/μL
  3. History of any immunodeficiency disease or condition other than HIV, chronic clinically significant illness or autoimmune disease
  4. Known positive result of screening for hepatitis B (surface antigen positive or detectable HBV DNA levels in blood) or hepatitis C (HCV RNA positive). Patient treated for HCV and assessed as cured by treating physician is eligible for the study
  5. Serious ongoing infection
  6. Abnormal liver biochemical tests > 2 x upper limit of normal (ULN) of aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (ALP)
  7. Total testosterone, LH or FSH levels at screening assessed as clinically abnormal by the Investigator
  8. Current treatment with testosterone
  9. History of any clinically significant kidney disease as determined by the Investigator or eGFR < 60 mL/min/1.73 m2 at screening. (Patients on dolutegravir with an eGFR<60 may be verified for study inclusion by analysis of cystatin C that should then be assessed as normal by the Investigator in order for the patient to be eligible)
  10. Diabetes mellitus or a fasting plasma blood glucose >7.0 mmol/L at screening
  11. Intolerance or contraindication to injectable triptorelin
  12. Vital signs, physical examination or lab results that exhibit evidence of acute illness
  13. Known history of moderate or severe depression (see definitions in ICD-10) within the past 5 years
  14. Any congenital or acquired prolongation of the QTc interval and use of any drugs that has been proven to prolong the QTc interval (Normal QTc interval defined as <450 msec)
  15. Involvement in any other drug study within 30 days prior to this study entry
  16. An increased PSA (Prostate Specific Antigen) value that is assessed as abnormal by the treating physician
  17. Any medical condition that in the opinion of the Investigator would compromise the patient's ability to participate in the study
  18. Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03536234


Contacts
Layout table for location contacts
Contact: Ola Winqvist, MD, PhD +46-70-5427939 ola.winqvist@israb.se

Locations
Layout table for location information
Germany
Zentrum für Infektiologie Berlin Prenzlauer Berg Recruiting
Berlin, Germany, 10439
Contact: Jukka Hartikainen, MD       hartikainen@zibp.de   
MVZ Karlsplatz Recruiting
Munich, Germany, 80335
Contact: Jukka Hartikainen, MD       hartikainen@zibp.de   
Sweden
Östra sjukhuset Recruiting
Göteborg, Sweden, 416 50
Contact: Piotr Nowak, MD PhD       Piotr.Nowak@ki.se   
Södersjukhuset Recruiting
Stockholm, Sweden, 118 83
Contact: Piotr Nowak, MD PhD       Piotr.Nowak@ki.se   
Karolinska University Hospital Huddinge Recruiting
Stockholm, Sweden, 141 86
Contact: Piotr Nowak, MD PhD       Piotr.Nowak@ki.se   
Sponsors and Collaborators
Immune System Regulation AB
Investigators
Layout table for investigator information
Study Director: Ola Winqvist, MD, PhD ISR AB
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Immune System Regulation AB
ClinicalTrials.gov Identifier: NCT03536234    
Other Study ID Numbers: ISR-003
First Posted: May 24, 2018    Key Record Dates
Last Update Posted: January 13, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
 Physiological Effects of Drugs
Contraceptive Agents, Hormonal
Antineoplastic Agents, Hormonal
Antineoplastic Agents